Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469386 | 0.86 | ALDH1A1 (0.72) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL7002726 | 0.79 | ALDH1A1 (0.56) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL9472659 | 0.76 | ALDH1A1 (0.59) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL393991 | 0.74 | ALDH1A1 (0.56) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL428217 | 0.74 | ALDH1A1 (0.56) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL840514 | 0.74 | ALDH1A1 (0.56) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL1747944 | 0.74 | ALDH1A1 (0.56) | ALDH1A1LMNAIDO1MEN1KMT2A | |
| SCHEMBL90440 | 0.74 | ALDH1A1 (0.56) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL515529 | 0.74 | ALDH1A1 (0.56) | ALDH1A1LMNAIDO1MEN1KMT2A | |
| SCHEMBL8358411 | 0.74 | ALDH1A1 (0.56) | ALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550598-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-23 | — | — | US | claimed |
| EP-1778669-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006023931-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-03-02 | — | — | WO | claimed |
| US-20060041137-A1 | Kinase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-02-23 | — | — | US | claimed |
| CN-102573480-B | Triazine derivatives and their therapeutic use | CALIFORNIA CAPITAL EQUITY LLC | 2015-06-10 | — | — | CN | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20090247554-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7550598-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-23 | — | — | US | disclosed |
| WO-2007117995-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-1778669-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006023931-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060041137-A1 | Kinase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-02-23 | — | — | US | disclosed |
| US-6960688-B2 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2005-11-01 | — | — | US | disclosed |
| EP-1501807-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093245-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216765-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | ALDH1A1 4068/4885LMNA 2516/4885IDO1 4071/4885 |
| US-20090247554-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | ALDH1A1 3886/4885LMNA 2107/4885IDO1 4124/4885 |
| US-20060041137-A1 | Kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | ALDH1A1 4393/4885LMNA 1878/4885IDO1 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.